{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:17:36Z","timestamp":1769606256605,"version":"3.49.0"},"reference-count":118,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T00:00:00Z","timestamp":1237420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The introduction of newer therapies for the treatment of multiple sclerosis has generated considerable optimism. That optimism has been tempered by the potential risks of these therapies, such as the risk for progressive multifocal leukoencephalopathy. A review of the possible causes of reactivation of JC virus in this population has illustrated the need to better understand the untoward effects of monoclonal antibody therapies and other immunomodulatory therapies currently being contemplated for use in multiple sclerosis. These drugs alter the immune response at different sites, and most, if not all, affect more than one aspect of host immunity. Drawing from existing experience with the use of these immunomodulatory therapies in other conditions and that available from the limited experience with multiple sclerosis, we review their potential untoward effects. The latter include a predisposition to opportunistic and community\u2010acquired infections, an altered response to vaccination, the development of cancers, and the appearance of autoimmune diseases. The identification of progressive multifocal leukoencephalopathy as a risk of therapy is relatively straightforward in light of its rarity and high morbidity and mortality, but a relatively slight increased risk for more common and less disabling disorders may be overlooked. Determining the actual risk frequency for many of these complications will likely require careful postmarketing surveillance. Ann Neurol 2009;65:367\u2013377<\/jats:p>","DOI":"10.1002\/ana.21630","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T13:44:35Z","timestamp":1237470275000},"page":"367-377","source":"Crossref","is-referenced-by-count":47,"title":["Opportunistic infections and other risks with newer multiple sclerosis therapies"],"prefix":"10.1002","volume":"65","author":[{"given":"Joseph R.","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Houff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,27]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2006.42.10.1042190"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"e_1_2_11_5_2","first-page":"1540","volume-title":"Neurological therapeutics: principles and practice","author":"Berger JR","year":"2006"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"e_1_2_11_9_2","unstructured":"2008 Biogen Idec Inc Cambridge M Panzara J Berger Important Tysabri information"},{"key":"e_1_2_11_10_2","unstructured":"PanzaraMA BaldinettiF BelcherG et al.Natalizumab utilization and safety in patients with relapsing MS: updated results from TOUCH and TYGRIS. World Congress on Treatment and Research in Multiple Sclerosis. Montreal Quebec September Canada 2008:P488."},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)31105-8"},{"issue":"1","key":"e_1_2_11_12_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13550280390195261","article-title":"Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions","volume":"9","author":"Berger JR","year":"2003","journal-title":"J Neurovirol"},{"key":"e_1_2_11_13_2","first-page":"403","volume-title":"Textbook of AIDS medicine","author":"Berger J","year":"1999"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/514032"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/344280"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537102"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/504947"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.2.253"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410310426"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2103"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199604000-00001"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.1.49"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490270405"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058122"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1005-1275"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.11.007"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002028"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.007"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21443"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21363"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159399.81861.D5"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20492"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.11.013"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.08.009"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-001-0684-y"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170122"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200403000-00006"},{"key":"e_1_2_11_39_2","article-title":"CellCept, myfortic labeling changes reflect PML risk","author":"Waknine Y","year":"2008","journal-title":"Medscape Today"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705548"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00147-004-0779-3"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)00804-5"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04612.x"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01641.x"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/504811"},{"key":"e_1_2_11_46_2","first-page":"25","article-title":"Natalizumab: first report of reactivation of herpesvirus infection: 3 case reports","volume":"1179","author":"Kister I","year":"2007","journal-title":"Reactions Weekly"},{"key":"e_1_2_11_47_2","unstructured":"Biogen. Tysabri 300 mg concentrate for solution for infusion. Available at:http:\/\/emc.medicines.org.uk\/emc\/assets\/c\/html\/displayDocPrinterFriendly.asp?documentid=18447. Accessed July 10 2008."},{"key":"e_1_2_11_48_2","unstructured":"WrayS.Varicella zoster encephalomyelitis and acute retinal necrosis with natalizumab. World Congress on Treatment and Research in Multiple Sclerosis Montreal Canada2008 p534."},{"key":"e_1_2_11_49_2","unstructured":"FrancisG. Natalizumab safety. Available at:www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007\u20104313s1\u201304\u2010Biogen\u2010Francis.ppt2007. Accessed on November 9 2008."},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00693.x"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl141"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2006.00751.x"},{"key":"e_1_2_11_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00013542-199701000-00004"},{"key":"e_1_2_11_57_2","first-page":"100","article-title":"Fatal viral encephalitis in children with X\u2010linked hypogammaglobulinemia","volume":"126","author":"Linnemann CC","year":"1973","journal-title":"Am J Dis Child"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705666"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.01.054"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2004.02.013"},{"key":"e_1_2_11_61_2","unstructured":"ColesA GroupCS.Alemtuzumab compared with subcutaneous high\u2010dose IFNB\u20101a in treatment\u2010naive relapsing\u2010remitting multiple sclerosis: primary efficacy outcomes of CAMMS223 at 3 years. Presented at: 60th Annual Meeting of the American Academy of Neurology; April 16 2008; Chicago."},{"key":"e_1_2_11_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670"},{"key":"e_1_2_11_63_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402653101"},{"key":"e_1_2_11_64_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000267662.41734.1f"},{"key":"e_1_2_11_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02284"},{"key":"e_1_2_11_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000121761.02129.A6"},{"key":"e_1_2_11_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052643"},{"key":"e_1_2_11_68_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.4.665"},{"key":"e_1_2_11_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2004.04.025"},{"key":"e_1_2_11_70_2","unstructured":"FTY720 trial continues despite death.2008. Accessed August 24 2008.http:\/\/www.mssociety.org.uk\/research\/newsinresearch\/researchnews\/fingolimod.html."},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346050-00007"},{"key":"e_1_2_11_72_2","first-page":"805","article-title":"Cladribine for the treatment of hematologic malignancies","volume":"12","author":"Baltz JK","year":"1993","journal-title":"Clin Pharm"},{"key":"e_1_2_11_73_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-199809050-00006"},{"key":"e_1_2_11_74_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721060-00005"},{"key":"e_1_2_11_75_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.4.1716"},{"key":"e_1_2_11_76_2","first-page":"323","article-title":"Effect of repeated treatments with cladribine (2\u2010chlorodeoxyadenosine) on blood counts in multiple sclerosis patients","volume":"43","author":"Grieb P","year":"1995","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_2_11_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.02.016"},{"key":"e_1_2_11_78_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154520.48391.69"},{"key":"e_1_2_11_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60918-6"},{"key":"e_1_2_11_80_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000203121.04509.31"},{"key":"e_1_2_11_81_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017903"},{"key":"e_1_2_11_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03094.x"},{"key":"e_1_2_11_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01292.x"},{"issue":"1","key":"e_1_2_11_84_2","first-page":"S85","article-title":"BG00012, a novel oral fumarate, is effective in patients with relapsing\u2010remitting multiple sclerosis","volume":"12","author":"Kappos L","year":"2006","journal-title":"Mult Scler"},{"key":"e_1_2_11_85_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.31908"},{"key":"e_1_2_11_86_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.9.1059"},{"key":"e_1_2_11_87_2","doi-asserted-by":"publisher","DOI":"10.1053\/srin.2002.36444"},{"key":"e_1_2_11_88_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.2.508"},{"key":"e_1_2_11_89_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-945530"},{"key":"e_1_2_11_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704116"},{"key":"e_1_2_11_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)80004-6"},{"key":"e_1_2_11_92_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000101434.98873.CB"},{"key":"e_1_2_11_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00592.x"},{"key":"e_1_2_11_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2007.00080.x"},{"key":"e_1_2_11_95_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.3.357-364.2003"},{"key":"e_1_2_11_96_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.68.4.337"},{"key":"e_1_2_11_97_2","first-page":"S38","article-title":"Vaccines for persons at high risk, 2007","volume":"56","author":"Zimmerman RK","year":"2007","journal-title":"J Fam Pract"},{"key":"e_1_2_11_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2007.00631.x"},{"key":"e_1_2_11_99_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023020-00002"},{"key":"e_1_2_11_100_2","first-page":"91","article-title":"Lymphoproliferative disorders and other tumors complicating immunodeficiencies","volume":"5","author":"Filipovich AH","year":"1994","journal-title":"Immunodeficiency"},{"key":"e_1_2_11_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2007.06174.x"},{"key":"e_1_2_11_102_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072739"},{"key":"e_1_2_11_103_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7997879"},{"key":"e_1_2_11_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0706103"},{"key":"e_1_2_11_105_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NT.0000324152.29773.31"},{"key":"e_1_2_11_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.02.070"},{"key":"e_1_2_11_107_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-007898"},{"key":"e_1_2_11_108_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10733"},{"key":"e_1_2_11_109_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01258.x"},{"key":"e_1_2_11_110_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035766"},{"key":"e_1_2_11_111_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0696-y"},{"key":"e_1_2_11_112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0800484"},{"key":"e_1_2_11_113_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704538"},{"key":"e_1_2_11_114_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.23"},{"key":"e_1_2_11_115_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209067618"},{"key":"e_1_2_11_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awl083"},{"key":"e_1_2_11_117_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.16.1887"},{"key":"e_1_2_11_118_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0706341"},{"key":"e_1_2_11_119_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.975"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.21630","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.21630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T18:12:56Z","timestamp":1697479976000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.21630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1002\/ana.21630"],"URL":"https:\/\/doi.org\/10.1002\/ana.21630","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}